Welcome to our dedicated page for Identa Rvice news (Ticker: IDTA), a resource for investors and traders seeking the latest updates and insights on Identa Rvice stock.
Identa Ltd Rvice (IDTA) delivers critical detection solutions for security and consumer markets through advanced forensic testing technology. This news hub provides authorized updates directly from the company, serving as the definitive source for stakeholders monitoring its operational and market developments.
Access real-time updates on product innovations, regulatory milestones, and strategic partnerships that drive IDTA's leadership in narcotics detection and diagnostic kits. Our curated feed includes earnings reports, manufacturing updates, and distribution network expansions essential for evaluating corporate health.
Key news categories cover product launches in forensic technology, financial performance updates, regulatory compliance achievements, and global distribution partnerships. Each update undergoes verification to ensure alignment with market disclosure standards.
Bookmark this page for streamlined access to IDTA's official communications. Combine our updates with third-party analysis through Stock Titan's research tools for comprehensive investment evaluation.
IDenta Corp (OTCQB: IDTA), a leader in Field Detection and Home Diagnostic Testing Kits, has reported significant financial growth in its 2024 annual report. The company achieved revenues of $1,455,488, up from $1,051,590 in 2023, while gross profit increased to $778,402 from $509,114.
Notable achievements include an impressive rise in operating profit to $305,805 from a loss of ($1,499) in 2023, and a substantial increase in net profit to $258,343 from $14,644. Cash and cash equivalents grew to $414,314 from $264,294.
The company attributes its success to strategic market expansion through new distributors, enhanced operational efficiency, and strong customer satisfaction initiatives.
IDenta Corp (OTCQB: IDTA), a leader in Field Detection and Home Diagnostic Testing Kits, reported strong Q3 2024 results with a 100% year-over-year revenue increase to $366,870. The company's financial performance showed significant improvements across all metrics, with gross profit rising to $274,542 and operating profit reaching $100,295, compared to a loss in Q3 2023. Net profit turned positive at $102,344, reversing the previous year's loss. Cash and cash equivalents strengthened to $469,615, up from $259,953 in Q3 2023.
IDenta Corp (OTCQB: IDTA), a leader in field detection and home diagnostic testing kits for narcotics, explosives, and forensic products, reported impressive Q2 2024 results. Despite global challenges, the company showed significant growth:
- Revenue increased to $360,988 from $188,494 in Q2 2023
- Gross profit rose to $258,326 from $124,934
- Operating profit improved to $72,558 from a loss of $76,350
- Net profit reached $79,901, compared to a loss of $76,334
- Cash and cash equivalents grew to $461,850 from $264,294
CEO Amichai Glattstein attributed the success to wise resource management, new customer acquisition, and expansion in existing markets. The company remains committed to creating a better future for the world through its innovative products in homeland security and consumer markets.
IDenta Corp (OTCQB: IDTA) will hold a Shareholders' Meeting on July 4th, 2024, at 10:00am ET / 5pm Israel time. The meeting will take place at the company's offices in Jerusalem, with a Zoom link available for global participation. CEO Amichai Glattstein announced that the agenda includes a proposed change in the company's structure, following preliminary approval by the board of directors and management. This meeting is a significant event for IDenta Corp, a leader in developing field detection and home diagnostic kits for narcotics, explosives, and forensic products in the Homeland Security and consumer markets.
IDenta Corp (OTCQB: IDTA), a global leader in developing field detection and home diagnostic testing kits for narcotics, explosives, and forensic products, has scheduled its 2024 shareholders' meeting.
The meeting will be held virtually on Monday, July 1st, 2024, at 10:00am EST / 5pm Israel Time via Zoom, accessible to participants worldwide.
CEO Amichai Glattstein expressed enthusiasm for the event, emphasizing the company's eagerness to engage with shareholders.
IDenta Corp (OTCQB: IDTA), a leader in Field Detection and Home Diagnostic Testing Kits for Narcotics, Explosives, and Forensic Products, reported a substantial improvement in its first quarter of 2024 financial results.
First Quarter 2024 highlights include revenues of $428,346, up from $231,623 in Q1 2023, and a gross profit increase to $354,118 from $179,482 in the same period. Operating profit soared to $176,067 compared to a loss of $45,375 in Q1 2023, while net profit reached $171,010, recovering from a loss of $25,554. Cash and cash equivalents also rose to $336,192 from $264,294 year-over-year.
CEO Amichai Glattstein attributed the success to expanded distribution, customer growth, and optimized production, positioning the company for sustained future growth.
IDenta Corp. (OTCQB: IDTA) reported its 2022 annual financial results, highlighting a sharp increase in net profit to $162,711, a 240% rise from 2021. This was driven by enhanced currency exchange rates and management efficiency. However, revenue declined by 4% to $1,338,754, with gross profit increasing by 5% to $1,123,021 due to production optimization. Operating profit fell 71% to $125,316, linked to costs from trade shows and production expansions. Cash reserves slightly rose to $368,901. CEO Amichai Glattstein emphasized a focus on the US market and product exposure as key growth strategies.
IDenta Corp. (OTCQB: IDTA), a leader in developing field detection and home diagnostic testing kits, reported its 2022 third quarter financial results on November 15, 2022. Key highlights include a 31% increase in gross profit to $287,451 and a significant turnaround in operating profit to $19,870 from a loss of $12,177 the previous year. Net profit rose to $19,419 from a loss of $45,792. However, cash and cash equivalents fell to $324,475 from $347,151 year-over-year. The CEO emphasized the company's strong recovery and ongoing partnerships amid a challenging economic environment.
IDenta Corp. (OTCQB: IDTA) has introduced a new test kit to detect Fentanyl in Cocaine and Crack, responding to the urgent need for safety amid rising drug contamination. CEO Amichai Glattstein emphasized the kit's potential life-saving capabilities, highlighting that Fentanyl is often undetectable by sight or taste. Available for purchase online under the brand Touch&Know, the kit offers quick results at an affordable price. IDenta is recognized for its leading role in developing diagnostic kits for drugs and explosives.
